| Execution period | 12 months |
|---|
NSE filing, NSE: ACCPL. Summary written from the filing by ALFA Finder's alert engine.
Accretion Pharmaceuticals Ltd: key numbers
- Share price
- ₹190.05
- Market cap
- ₹211.3 Cr
- Revenue (annual)
- ₹89.63 Cr
- Net profit (annual)
- ₹9.67 Cr
- P/E (TTM)
- 21.9×Sector 45.9×
- Promoter holding
- 73.52%+0.00% QoQ
- FII holding
- 0.17%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Accretion Pharmaceuticals Ltd
All →Accretion Pharmaceuticals Results Update
Accretion Pharmaceuticals reported H1 FY27 net revenue up 25.83% to ₹55.04 crore and PAT up 72.63% to ₹8.20 crore via media release. EBITDA margin improved to 22.48%.
Accretion Pharmaceuticals H1 FY27 Results: Net Profit ₹8.2 Cr, Up 70.8% YoY
Accretion Pharmaceuticals reported unaudited standalone half-year results to 30 September 2026, with revenue of Rs 5,504.10 lakh and profit after tax of Rs 820.14 lakh. The results carry a limited review report from VSSB & Associates.
- Key figure
- Net profit ₹8.2 Cr · +70.8% YoY
Accretion Pharmaceuticals Annual General Meeting
Accretion Pharmaceuticals Limited announced the results of its postal ballot, where shareholders approved five special resolutions, including increasing borrowing limits and charging company assets.
Accretion Pharmaceuticals Other Announcement
Accretion Pharmaceuticals Limited submitted the confirmation certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.
Accretion Pharmaceuticals Annual General Meeting
Accretion Pharmaceuticals Limited issued a postal ballot notice to shareholders to seek approval for altering the company's Memorandum of Association (Object Clause).
Accretion Pharmaceuticals Other Announcement
Accretion Pharmaceuticals Limited approved an alteration to its Memorandum of Association to expand its business objects. The Board also approved increased borrowing and investment limits subject to shareholder approval.
Other board meeting outcome announcements
All →Pasari Spinning Mills Board Meeting Outcome
Pasari Spinning Mills reconstituted its Audit, NRC and SRC committees after an independent director resigned and Ms. Bhavna Agrawal was appointed. The change takes effect from the 30 October 2026 board meeting.
Teja Engineering Industries Board Meeting Outcome
Teja Engineering Industries informed NSE that its board appointed K. J. Tapiawala & Associates as internal auditor and N R Shah & Co as secretarial auditor for FY 2026-27. Both are routine appointments with no monetary value.
- Execution
- FY 2026-27
SC Agrotech Board Meeting Outcome
SC Agrotech's board approved shifting its corporate office to Sola, Ahmedabad, effective October 31, 2026. The registered office stays unchanged in Delhi.
Abril Paper Tech Board Meeting Outcome
Abril Paper Tech appointed K. J. Tapiawala & Associates as internal auditor for FY 2026-27. The appointment is a routine auditor change with no financial or operational impact.
- Execution
- Financial Year 2026-27
Bridge Securities Board Meeting Outcome
Bridge Securities' board approved moving its registered office within Ahmedabad, effective 31 October 2026. The routine administrative change has no financial impact.
VCU Data Management Board Meeting Outcome
VCU Data Management appointed M/s. Utkarsh Shah & Co. as Secretarial Auditors for five years from FY 2026-27, subject to AGM approval. No monetary amount is disclosed, so this is an auditor appointment intimation.
- Execution
- FY 2026-27 to 2030-31 (five years)